Last updated: February 15, 2026
Overview
NDC 00169-2800 is a prescription medication marketed by MAVYRET (glecaprevir/pibrentasvir). It treats chronic hepatitis C virus (HCV) infection across genotypes 1-6. The drug's market presence hinges on demand for HCV therapies, regulatory dynamics, and competitive landscape.
Market Size and Demand
The global hepatitis C market was valued at approximately $12 billion in 2022, with the U.S. representing around 50% of the market. The U.S. HCV patient population estimated at 2.4 million people, with prescription rates steady due to updated guidelines favoring short-duration, interferon-free regimens.
The growth trajectory is influenced by:
- Increased screening efforts.
- Patient diagnosis rates.
- Adoption of pangenotypic treatments like MAVYRET.
- Competition from other direct-acting antivirals (DAAs), including Epclusa (gilead) and Zepatier (merck).
Market Dynamics
The drug's key differentiators are its broad genotype coverage and shortened therapy duration (8-16 weeks). MAVYRET's approval in 2019 has boosted its market share, capturing approximately 25% of recent DAA prescriptions, with upward potential as awareness rises.
Factors influencing demand include:
- Cost reimbursement policies.
- Patient access programs.
- Physician prescribing patterns.
Pricing Landscape
List prices for hepatitis C treatments vary widely but often stabilize around $24,000 to $80,000 per treatment course. MAVYRET’s list price in the U.S. is approximately $26,400 per 8-week course.
Insurance payer negotiations and discounts impact net prices, with actual transaction prices typically falling 20-50% below list.
Historical Price Trends
Mavyret's pricing remained stable since its launch, responding to market competition and payer pressure. Unlike earlier HCV drugs that saw steep discounts, MAVYRET's short therapy and broad coverage have sustained its price point.
Price Projections (Next 3–5 Years)
Assuming market expansion and increased diagnosis:
- Price stability expected, with minor reductions (~5%) driven by payer negotiations.
- Competition may lead to additional discounts, particularly if new regimens enter the market.
- Volume growth expected as screening programs expand, offsetting slight per-unit price declines.
Projected Revenue Scenarios:
| Year |
Estimated Prescriptions |
Average Net Price per Course |
Revenue Estimate |
Comments |
| 2023 |
400,000 |
$21,000 |
$8.4 billion |
Steady demand; moderate discounting due to competition |
| 2024 |
440,000 |
$20,000 |
$8.8 billion |
Increased diagnosis and treatment uptake |
| 2025 |
480,000 |
$19,000 |
$9.1 billion |
Market saturation; possible price competition |
Competitive Landscape and Risks
Competitors include:
- Epclusa (Gilead) – pangenotypic, high market share.
- Zepatier (Merck) – genotype-specific.
- New regimens under clinical trials offering shorter courses or enhanced efficacy.
Risks impacting pricing and volume include:
- Regulatory shifts favoring generics.
- Patent expirations.
- Changes in healthcare reimbursement policies that could cap prices.
Regulatory and Policy Impact
Changes in Medicare/Medicaid reimbursement policies, as well as FDA/Kaiser guidelines, can influence pricing strategies. Patent protection is valid until at least 2028, supporting exclusivity and pricing power.
Conclusion
NDC 00169-2800 is positioned as a leading hep C treatment with stable but competitive pricing. Volume growth driven by expanded screening and diagnosis will underpin revenue increases, with moderate downward pressure on prices over time.
Key Takeaways
- Market size driven by U.S. diagnosed population and treatment uptake.
- List price: ~$26,400; net prices likely 20–50% lower.
- Stable pricing with slight discounts forecasted over next five years.
- Revenue growth supported by increased prescription volume, despite competition.
- Patent protection until 2028 offers pricing stability in the near term.
FAQs
-
What is the current list price of MAVYRET (NDC 00169-2800)?
Approximately $26,400 per 8-week course.
-
How does MAVYRET compare price-wise to competitors?
Similar overall pricing; its streamlined regimen and broad genotype coverage support its market position, with net prices typically discounted 20–50%.
-
What are the primary factors affecting damage to MAVYRET’s revenue?
Entry of new competitors, patent expirations after 2028, changing reimbursement policies, and generic market options.
-
What is the estimated treatment volume for MAVYRET in 2023?
About 400,000 prescriptions, subject to regional variations and screening program effectiveness.
-
How might future price discounts impact revenue?
Moderate discounts (5–10%) may occur due to market competition, but overall volume increases will sustain growth.
Sources
[1] EvaluatePharma, "Global Hepatitis C Virus (HCV) Market Forecast," 2022.
[2] Medicare and Medicaid pricing policies, U.S. Health Economics Data, 2023.
[3] Gilead Sciences, "Epclusa Price and Market Share Data," 2022.
[4] Merck & Co., "Zepatier Market Analysis," 2022.
[5] FDA Drug Approvals and Patent Data, 2022.
